New androgen biosynthesis inhibitor drug for prostate cancer shows conflicting results
A new androgen biosynthesis inhibitor drug improved the progression-free survival of prostate cancer, but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology. The findings are a testament to the extent of prostate cancer treatment, according to Maha Hussain, MD, Professor of Medicine Genevieve …
New androgen biosynthesis inhibitor drug for prostate cancer shows conflicting results Read More »